Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Reviewer: Ryan Smith, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 26 de septiembre del 2003
Authors: Shasha D, George MJ, Harrison LB
Source: Cancer, 2003;98:1072-9
Patients undergoing treatment for cancer with radiation therapy and chemotherapy often have anemia. This can cause profound fatigue with associated decreased quality of life, as pointed out by the authors. Anemia has also been shown to decrease cure rate in cervical and head and neck tumors. Therefore, it is imperative that anemia, especially severe anemia, be rectified. This study demonstrates that weekly epoetin-α can be used safely and efficaciously in this regard. However, this was a single arm, nonrandomized study in which several hundred of the patients were not evaluable for hemoglobin response or quality of life. Most were dropped because they did not meet the minimum radiation requirements, though this still could have skewed the data. Seventy four per cent of patients had a response to epoetin-α as measured by a 2 g/dl increase or a hemoglobin of > 12 g/dl with associated decrease in transfusion requirement and increase in quality of life. However, these parameters could be achieved at any point during the study, which was up to 16 weeks. Therefore, though the efficacy was high, its onset could have also been very slow. This is a large disadvantage in patient symptom relief and especially cancer treatment efficacy. Another aspect of the study not reported is cost. Epoetin-α is an expensive medication, especially if achieving efficacy means increasing the dose to 60,000 units per week. This should also be considered before initiating therapy. Therefore, although epoetin-α is efficacious and safe, it is often also slow in onset with a high expense. Transfusions increase the hemoglobin immediately and may be better in some patients. However, this increase in hemoglobin with transfusion may be short-lived. In addition, blood bank resources are finite, there is always the risk of infection or immunosuppression, and there is a cost associated with transfusion as well. Therefore, weekly administration of epoetin-α is a good alternative to transfusion, as long as the disadvantages are considered.
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults